Clinical trials: Myelodysplastic Neoplasm
Lymphoma, Myeloma
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high.
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia
- Trial name
- NCT00580034
- Testing
- Campath Purged Non-myeloablative ASCT, Donor Apheresis
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- David Rizzieri, MD
Chronic Myeloproliferative Disorders, Leukemia
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
Patients are being asked to participate in this study because they have a malignant blood disease such as Myelodysplastic Syndrome (MDS), Myeloproliferative Disorder (MPD), Acute Myelogenous Leukemia (AML) or Chronic Myelogenous…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes
- Trial name
- MPDMDSBMT (NCT00069992)
- Testing
- Total Body Irradiation, Fludarabine, Campath 1H
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Baylor College of Medicine
Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Phase I/II trial to study the effectiveness of liposomal daunorubicin and SU5416 in treating patients who have hematologic cancer that has not responded to initial therapy.
- Conditions
- Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
- Trial name
- NCT00005942
- Testing
- liposomal daunorubicin citrate, semaxanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
This study will evaluate the long-term safety of ARD103 cellular therapies
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory, MDS (Myelodysplastic Syndrome)
- Trial name
- NCT06906380
- Testing
- Non interventional study
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- ARCE Therapeutics, Inc.
Immune Thrombocytopenia, Myelodysplastic Syndromes
Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)
Current diagnostic criteria for Immune ThrombocytoPenia (ITP) are mainly based on the presence of low numbers of platelets, excluding other multiple causes of thrombocytopenia, including immunodeficiencies, constitutional or…
- Trial name
- NCT03469661
- Where
- 6 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Myelodysplastic Syndromes
Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)
Chronic anemia is the symptom most frequently found at diagnosis in low risk myelodysplastic syndrome. It generates an increased rate of morbidity and mortality in this population of patients whose median age is high and the rate…
- Trial name
- EPO-QoL (NCT02428686)
- Testing
- Epoetin beta (NeoRecormon)
- Where
- 31 sites in France
- Volunteers
- 50 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
- Conditions
- Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome
- Trial name
- NCT04734990
- Testing
- Azacitidine, Seclidemstat
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria
The complement system is an important component of the innate immune system. Abnormal activation, inadequate regulation and control of the complement system, as well as impaired and dysfunctional effector functions, underlie…
- Trial name
- VSA012-1002 (NCT06848296)
- Testing
- VSA012
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Bisirna Therapeutics Pte. Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
This phase Ib trial studies the side effects and best dose of pembrolizumab and how well it works in combination with decitabine with or without venetoclax in treating patients with acute myeloid leukemia or myelodysplastic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
- Trial name
- NCT03969446
- Testing
- Decitabine, Pembrolizumab, Venetoclax
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Effect of Food on Blood Levels of ASTX727
This study is designed to examine blood levels of ASTX727, a fixed-dose combination tablet containing the combination of cedazuridine (100 mg) and decitabine (35 mg), when given under fed versus fasted conditions to participants…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03813186
- Testing
- ASTX727 + Day 2 Food, ASTX727 + Day 4 Food
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Bone Marrow Failure Syndromes, Erythrocyte Disorder
Investigation of the Genetics of Hematologic Diseases
The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases.
- Conditions
- Bone Marrow Failure Syndromes, Erythrocyte Disorder, Leukocyte Disorder, Hemostasis
- Trial name
- NCT02720679
- Where
- United States
- Volunteers
- 1,716 people
- Sponsor
- St. Jude Children's Research Hospital
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
NK Cells in Cord Blood Transplantation
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Trial name
- NCT01619761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-005 in healthy volunteers.
- Trial name
- NCT06294301
- Testing
- LP-005 Dose 1 (Single), LP-005 Dose 2 (Single), LP-005 Dose 3 (Single)
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Longbio Pharma
Myelodysplastic Syndrome (MDS)
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
Primary Outcome Measures: To evaluate the efficacy of treatment with Azacitidine in patients with transfusion-dependent, low risk International Prognostic Scoring System (IPSS) 0 int-1, Myelodysplastic Syndrome (MDS) without…
- Trial name
- ABRAZA (NCT01338337)
- Testing
- Azacitidine
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Asociación Andaluza de Hematología y Hemoterapia
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003602
- Testing
- cytarabine, etoposide, idarubicin
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Riverside Haematology Group
Myelodysplastic Syndromes
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This was originally designed as a phase I/II trial studying the side effects of sodium stibogluconate and how well…
- Trial name
- NCT01009502
- Testing
- sodium stibogluconate
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Myelodysplastic Syndrome, MDS
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
The purpose of this open label study is to determine whether combining pracinostat (study drug) with Vidaza (azacitidine) or Dacogen (decitabine) will improve clinical responses in Myelodysplastic Syndrome (MDS) patients who have…
- Trial name
- MEI-005 (NCT01993641)
- Testing
- pracinostat, Azacitidine, Decitabine
- Where
- 21 sites in United States
- Volunteers
- 45 people
- Sponsor
- Helsinn Healthcare SA
Myelodysplastic Syndrome
Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
This study will determine the safety and effectiveness of a combination of the immune-suppressing drugs antithymocyte globulin (ATG) and cyclosporine for treating myelodysplasia, a disorder of low blood cell counts.
- Trial name
- NCT00005937
- Testing
- Antithymocyte globulin, Cyclosporine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Neal Young, M.D.
Myelodysplastic Syndrome (MDS)
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-001 in healthy volunteers.
- Trial name
- NCT06294275
- Testing
- LP-001 Dose 1 (Single), LP-001 Dose 2 (Single), LP-001 Dose 3 (Single)
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Longbio Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.